Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • NextGenSeq
    replied
    You could check their website.


    ASHG 2013. Oxford Nanopore will be exhibiting at ASHG 2013 in Boston, 22-26 October. http://www.ashg.org/2013meeting/

    Leave a comment:


  • BBoy
    replied
    Originally posted by GenoMax View Post
    They just raised $64 Million this month: http://nextgenseek.com/2013/10/oxfor...es-64-million/ Clearly investors must have seen something that we do not have access to (yet).
    Maybe they were shown the foils from AGBT 2011 :-)

    Leave a comment:


  • GenoMax
    replied
    Originally posted by bstamps View Post
    I'm guessing


    Either they release something, or risk losing funding from investors at this point. My bet is that they release the Minion sooner than the Gridion.
    They just raised $64 Million this month: http://nextgenseek.com/2013/10/oxfor...es-64-million/ Clearly investors must have seen something that we do not have access to (yet).
    Last edited by GenoMax; 10-18-2013, 10:48 AM.

    Leave a comment:


  • bstamps
    replied
    I'm guessing


    A) 100%
    B) 75/25. Either they release something, or risk losing funding from investors at this point. My bet is that they release the Minion sooner than the Gridion.

    Leave a comment:


  • GenoMax
    replied
    Hopefully they are not going to wait till illumina's "right to negotiate" expire at end of 2016?
    Last edited by GenoMax; 10-18-2013, 09:34 AM.

    Leave a comment:


  • GW_OK
    replied
    So.
    ASHG next week.
    Any care to give odds on ONT:
    A) Being present?
    B) Announcing anything? (Announcing no announcements does not count)

    To aid in your handicapping, a certain Clive Brown tweeted:
    Clive G. Brown ‏@Clive_G_Brown 9 Oct

    I've reluctantly rejoined twitter purely so that I can make one tweet - when the appropriate time arises ...
    Also, it appears the Minion is now sporting a new look.

    Leave a comment:


  • GenoMax
    replied
    Originally posted by nickloman View Post
    Given that they are continuously screening new and better pores and that is in fact one of the cool things about a biological nanopore (just like other sequencing companies regularly screen for new polymerases), I didn't necessarily see that as reflective of where they are in the product development pipeline.
    No argument there.

    We all hope they will stop the screening at some point and release the first product we can use.

    Leave a comment:


  • nickloman
    replied
    Originally posted by ECO View Post
    Seriously though, having been through the bring up of a single molecule sequencer...if the CTO is opining in a bar to a blogger about improving consensus accuracy by throwing in multiple types of pores...they are a LONG way from finalizing a chemistry, let alone stabilizing and commercializing it.
    Just to note I added a clarification from Clive at the bottom of the post on that particular point...

    Given that they are continuously screening new and better pores and that is in fact one of the cool things about a biological nanopore (just like other sequencing companies regularly screen for new polymerases), I didn't necessarily see that as reflective of where they are in the product development pipeline.

    Leave a comment:


  • GenoMax
    replied
    Originally posted by ECO View Post
    And I hope I'm not off Clive's list.
    Perhaps not before this post.

    But now you can't be sure

    Leave a comment:


  • ECO
    replied
    Waaaaaa we made promises we couldn't keep to get attention and funding...and now people expect us to keep them!

    <tiny violin playing>

    Seriously though, having been through the bring up of a single molecule sequencer...if the CTO is opining in a bar to a blogger about improving consensus accuracy by throwing in multiple types of pores...they are a LONG way from finalizing a chemistry, let alone stabilizing and commercializing it.

    Happy to eat words. Actually I love having my pessimism proven wrong.

    And I hope I'm not off Clive's list. I could do some long range clinical haplotyping pretty easily!

    Leave a comment:


  • Jeremy
    replied
    Originally posted by Clive
    ([url
    http://pathogenomics.bham.ac.uk/blog/2013/03/a-chat-with-oxford-nanopores-clive-brown-at-agbt-2013[/url])
    “We didn’t even know that long reads were so important to people until after that AGBT presentation.”
    Really? I find that hard to believe.
    Last edited by Jeremy; 03-06-2013, 05:41 PM.

    Leave a comment:


  • seqnextgen
    replied
    Originally posted by krobison View Post
    I thought it was a joke originally, obviously, pathogenomics did find a MiniIon in AGBT. This is probably more comprehensive non-update one can find now

    Leave a comment:


  • GW_OK
    replied
    Originally posted by krobison View Post
    I confess that I did stroll through the beach area around the suites (on my way to my next meeting! I was going through there anyway, honest!) looking for disturbed sand patches.

    I should have been stalking the bar, apparently.

    Leave a comment:


  • BBoy
    replied
    Originally posted by krobison View Post
    Apparently we have all been asleep at the wheel. The minion has been out for decades, the first model has even made it to a museum:
    Almost... I had a very enjoyable trip to the Science Museum in London this weekend and whilst there was amazed to see an Oxford Nanopore DN...

    Leave a comment:


  • krobison
    replied
    Originally posted by seqnextgen View Post
    AFAIK, nothing..... no data, no status update, not even a cool USB sequencer full with data found in a bar
    What? You weren't out on the strand digging through sand like a madman?

    Leave a comment:

Latest Articles

Collapse

  • seqadmin
    Essential Discoveries and Tools in Epitranscriptomics
    by seqadmin




    The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...
    04-22-2024, 07:01 AM
  • seqadmin
    Current Approaches to Protein Sequencing
    by seqadmin


    Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
    04-04-2024, 04:25 PM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, Yesterday, 08:47 AM
0 responses
16 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-11-2024, 12:08 PM
0 responses
60 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 10:19 PM
0 responses
60 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 09:21 AM
0 responses
54 views
0 likes
Last Post seqadmin  
Working...
X